GGrantIndex
← Leaderboards

Debra Ellyn Weese-Mayer

Lurie Children'S Hospital Of Chicago

Google Scholar ↗PubMed ↗ORCID ↗
$3,635,994
Attributed
$9,715,227
Total exposure
4
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2M · FY2016–25
$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$8,915,227 · 3
FDA$800,000 · 1

By mechanism

R01$6,879,745 · 2
U01$2,680,482 · 1
R03$155,000 · 1

Top collaborators

Most similar at Lurie Children'S Hospital Of Chicago

Same institution · by research overlap

Others in their field

Top investigators on “Impairment”

Research focus

ImpairmentOxygenRespiratoryPhysiologicalPharmaceutical PreparationsLifeFutureSensoryMotorPremature InfantPregnancyResponsePatternPremature BirthNeonatalChildBronchopulmonary DysplasiaInfantInnovationPrematureResolutionEarly IdentificationNervous System PhysiologyMorbidity - Disease Rate

Grant awards (15)

Post-Vent, the Sequelae: Personalized Prognostic Modeling for Consequences of Neonatal Intermittent Hypoxemia in Preterm Infants at Pre-School Age$1,587,757
R01 · FY2025 · HL · contact PI
Progressing toward clinical trial readiness in CCHS: Natural history study to incorporate patient voice, harmonize clinical and registry data, and standardize assessments$400,000
R01 · FY2025 · FD · contact PI
Post-Vent, the Sequelae: Personalized Prognostic Modeling for Consequences of Neonatal Intermittent Hypoxemia in Preterm Infants at Pre-School Age$1,485,040
R01 · FY2024 · HL · contact PI
Progressing toward clinical trial readiness in CCHS: Natural history study to incorporate patient voice, harmonize clinical and registry data, and standardize assessments$400,000
R01 · FY2024 · FD · contact PI
Post-Vent, the Sequelae: Personalized Prognostic Modeling for Consequences of Neonatal Intermittent Hypoxemia in Preterm Infants at Pre-School Age$1,521,329
R01 · FY2023 · HL · contact PI
PHOX2B Congenital Central Hypoventilation Syndrome (CCHS) Physiologic Signatures in Readiness for Future Clinical Trials$77,500
R03 · FY2023 · TR · contact PI
Post-Vent, the Sequelae: Personalized Prognostic Modeling for Consequences of Neonatal Intermittent Hypoxemia in Preterm Infants at Pre-School Age$1,485,619
R01 · FY2022 · HL · contact PI
PHOX2B Congenital Central Hypoventilation Syndrome (CCHS) Physiologic Signatures in Readiness for Future Clinical Trials$77,500
R03 · FY2022 · TR · contact PI
Integrated analysis of autonomic biomarkers in prematurity-related ventilatory control: Determination of neurorespiratory maturation and predictors of co-morbidity risk$530,569
U01 · FY2020 · HL
EVALUATING THE INTEGRATION OF CARDIOVASCULAR, RESPIRATORY, AND CEREBROVASCULAR STABILITY AND MATURATION AND THEIR EFFECT ON RESPIRATORY AND NEUROLOGIC MORBIDITY IN PRETERM INFANTS$249,607
U01 · FY2020 · HL · contact PI
Integrated analysis of autonomic biomarkers in prematurity-related ventilatory control: Determination of neurorespiratory maturation and predictors of co-morbidity risk$578,223
U01 · FY2019 · HL
Integrated analysis of autonomic biomarkers in prematurity-related ventilatory control: Determination of neurorespiratory maturation and predictors of co-morbidity risk$535,064
U01 · FY2018 · HL
Autonomic Neurorespiratory Stability and Maturation in Preterm Infants: Assessment of Impact on Early Markers of Neurodevelopment$50,175
U01 · FY2018 · HL
Integrated analysis of autonomic biomarkers in prematurity-related ventilatory control: Determination of neurorespiratory maturation and predictors of co-morbidity risk$545,870
U01 · FY2017 · HL
Integrated analysis of autonomic biomarkers in prematurity-related ventilatory control: Determination of neurorespiratory maturation and predictors of co-morbidity risk$190,974
U01 · FY2016 · HL